GLPwatch
Papers (12034)
Page 128 of 201, ranked by citation count.
- Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?
- Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.
- GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.
- Pre-pregnancy treatment of semaglutide improves high-fat-diet-induced placental and fetal hypothalamic alterations in a sex-specific manner in rats†.
- A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.
- GLP-1R/NPY2R regulate gene expression, ovarian and adrenal morphology in HFD mice.
- Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.
- Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis.
- Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.
- In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.
- Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.
- Treatment of obese diabetics.
- Exenatide enhances INS-1 rat pancreatic β‑cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein.
- Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.
- [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
- The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.
- Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
- Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways.
- Tirzepatide Trial Demonstrates Substantial Weight Loss.
- Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
- Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
- Exenatide once weekly in type 2 diabetes mellitus.
- Exendin-4 Induces Cytotoxic Autophagy in Two Ovarian Cancer Cell Lines through Inhibition of Mtorc1 Mediated by Activation of AMPK and Suppression of Akt.
- Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.
- Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.
- The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.
- Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.
- Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide.
- A Pharmacological Dose of Liraglutide Improves Mitochondrial Performance in Mouse Leydig Cells.
- Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development.
- Tirzepatide: A New Anti-Obesity Medication.
- Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
- The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients.
- Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.
- Exenatide modulates visual cortex responses.
- Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
- Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.
- Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
- SGLT-2 Inhibitors' and GLP-1 Receptor Agonists' Influence on Neuronal and Glial Damage in Experimental Stroke.
- A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.
- Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
- Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.
- Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide.
- Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
- Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
- Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.
- Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis.
- Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
- Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus.
- Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.
- Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.
- Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.
- The First Triple Agonist for Antiobesity: Retatrutide.
- Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report.
- IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
- Aptamer Functionalized Liposomes Co-Loaded with Exenatide-4 and Coenzyme Q10 Ameliorate Type 2 Diabetes Mellitus by Improving Pancreatic β Cell Function.
- Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.